Fate Therapeutics to Webcast Conference Call Reporting First Quarter 2023 Financial Results

Rhea-AI Summary

Fate Therapeutics, a clinical-stage biopharmaceutical company, will host a conference call on May 3, 2023, at 5:00 PM ET to discuss its financial results for Q1 2023. The company is pioneering induced pluripotent stem cell (iPSC)-derived cellular immunotherapies aimed at treating cancer and autoimmune disorders. Participants can register for the call via a provided link and access the live webcast on the company’s website, under the 'Investors' section. An archived version of the webcast will be available shortly after the event. Fate Therapeutics specializes in multiplexed-engineered iPSC lines and aims to deliver innovative cell therapies that incorporate synthetic controls such as chimeric antigen receptors (CARs).

Positive

• Hosting a Q1 2023 earnings call on May 3, 2023, indicates proactive investor engagement.
• Focused on innovative cancer therapies with a strong emphasis on iPSC-derived products.

Negative

• None.

SAN DIEGO, April 24, 2023 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (the “Company” or “Fate Therapeutics”) (NASDAQ: FATE), a clinical-stage biopharmaceutical company dedicated to bringing a first-in-class pipeline of induced pluripotent stem cell (iPSC)-derived cellular immunotherapies to patients with cancer and autoimmune disorders, today announced that the Company will host a conference call and live audio webcast on Wednesday, May 3, 2023 at 5:00 PM ET to report its first quarter 2023 financial results and provide a corporate update.

In order to participate in the conference call, please register using the conference link here. The live webcast can be accessed under "Events & Presentations" in the Investors section of the Company's website at www.fatetherapeutics.com. The archived webcast will be available on the Company's website beginning approximately two hours after the event.

About Fate Therapeutics, Inc.

Fate Therapeutics is a clinical-stage biopharmaceutical company dedicated to bringing a first-in-class pipeline of induced pluripotent stem cell (iPSC)-derived cellular immunotherapies to patients with cancer and autoimmune disorders. Using its proprietary iPSC product platform, the Company has established a leadership position in creating multiplexed-engineered iPSC lines and in the manufacture and clinical development of off-the-shelf, iPSC-derived cell products. The Company’s effector cell pipeline includes multiplexed-engineered, iPSC-derived natural killer (NK) cell and T-cell product candidates, which incorporate novel synthetic controls of cell function, such as chimeric antigen receptors (CARs) to target tumor-associated antigens and are intended to deliver multiple mechanisms of therapeutic importance to patients including in combination with well-established cancer therapies. Fate Therapeutics is headquartered in San Diego, CA. For more information, please visit www.fatetherapeutics.com.

Contact:
Matthew Guido
Stern Investor Relations, Inc.
212-362-1200
matthew.guido@sternir.com

FAQ

When is Fate Therapeutics' Q1 2023 earnings call scheduled?

The earnings call for Q1 2023 is scheduled for May 3, 2023, at 5:00 PM ET.

What will Fate Therapeutics discuss in the upcoming conference call?

The company will report its Q1 2023 financial results and provide a corporate update.

How can I access the Fate Therapeutics conference call?

You can register for the call via the provided link in the press release and access the webcast on the company’s website.

What is the focus of Fate Therapeutics' research and products?

Fate Therapeutics specializes in developing induced pluripotent stem cell (iPSC)-derived cellular immunotherapies for cancer and autoimmune disorders.